The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer

APMIS

Volumn 107, Issue 1, 1999, Pages 160-167

  Brünner, Nils ^a   Nielsen, Hans Jørgen ^b   Hamers, Maria ^a   Christensen, Ib Jarle ^a   Thorlacius Ussing, Ole ^c   Stephens, Ross W ^a  

^a FINSEN LABORATORY   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cancer; Prognosis; suPAR; UPAR

Indexed keywords

UROKINASE RECEPTOR;

BREAST CANCER; CANCER INVASION; COLON CANCER; DIAGNOSTIC VALUE; HUMAN; LUNG CANCER; METASTASIS POTENTIAL; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; RECEPTOR DENSITY; REVIEW;

EID: 0033003596     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1699-0463.1999.tb01539.x     Document Type: Review

References (62)

1. 1. Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 1995;61:597-600.
2. 2. Fernö M, Bendahl P-O, Borg Å, Brundell J, Hirschberg L, Olsson H, Killander D. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Eur J Cancer 1996;32A:793-801.
3. 3. Foekens JA, Schmitt M, van Putten WL, Peters HA, Kramer MD, Janicke F, Klijn JG. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994;12:1648-58.
4. 4. Foekens JA, Schmitt M, van PW, Peters HA, Bontenbal M, Janicke F, Klijn JG. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992;52:6101-5.
5. 5. Grøndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K, Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993;53:2513-21.
6. 6. Grøndahl-Hansen J, Peters HA, van Putten WL, Look MP, Pappot H, Rønne E, et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clinical Cancer Res 1995;1:1079-87.
7. 7. Grøndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K, Brünner N. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. Clinical Cancer Res 1997;3:233-9.
8. 8. Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch RW, Schildberg FW. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1995;1:1035-9.
9. 9. Hofmann R, Lehmer A, Buresch M, Hartung R, Ulm K. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer 1996;78:487-92.
10. 10. Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 1994;54:2527-30.
11. 11. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H, Graeff H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993;24:195-208.
12. 12. Jänicke F, Schmitt M, Ulm K, Gossner W, Graeff H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer [letter]. Lancet 1989;2:1049.
13. 13. Jänicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Semin Thromb Hemostasis 1991;17:303-12.
14. 14. Jänicke F, Thomssen C, Pache L, Schmitt M, Graeff H. Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients. In: Scmitt M, et al., editors. Prospects in diagnosis and treatment of breast cancer. Elsevier Science B.V: 1994. p.207-18.
15. 15. Kobayashi H, Fujishiro S, Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 1994;54:6539-48.
16. 16. Kuhn W, Pache L, Schmalfeldt B, Dettmar P, Schmitt M, Jänicke F, Graeff H. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gyn Oncol 1994; 401-9.
17. 17. Pappot H, Gaardsvoll H, Rømer J, Pedersen AN, Grøndahl-Hansen J, Pyke C, Brünner N. Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications. Biol Chem Hoppe Seyler 1995;376:259-67.
18. 18. Pappot H, Høyer-Hansen G, Rønne E, Hansen HH, Brünner N, Danø K, Grøndahl-Hansen J. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer 1997;33:867-72.
19. 19. Pedersen H, Brünner N, Francis D, Østerlind K, Rønne E, Hansen HH, et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994;54:4671-5.
20. 20. Pedersen H, Grøndahl-Hansen J, Francis D, Østerlind K, Hansen HH, Danø K, Brünner N. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 1994;54:120-3.
21. 21. Plebani M, Herszènyi L, Carraro P, Paoli MD, Roveroni G, Cardin R, et al. Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role. Clin Exp Metastasis 1997;15:418-25.
22. 22. Sier CFM, Stephens RW, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Danø K, Brünner N, Blasi F. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998;58:1843-9.
23. 23. Stephens RW, Pedersen NA, Nielsen HJ, Hamers MJAG, Høyer-Hansen G, Rønne E, et al. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 1997;43:1868-76.
24. 24. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Danø K, Brünner N. Soluble urokinase receptor in preoperative plasma is an independent prognostic variable in patients with colorectal cancer. Proc Am Ass Cancer Res 1998;39:# 325.
25. 25. Nielsen LS, Hansen JG, Skriver L, Wilson EL, Kaltoft K, Zeuthen J, Danø K. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry 1982;21:6410-15.
26. 26. Skriver L, Nielsen LS, Stephens R, Danø K. Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virus. Eur J Biochem 1982;124:409-14.
27. 27. Petersen LC, Lund LR, Nielsen LS, Danø K, Skriver L. One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem 1988;263:11189-95.
28. 28. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985;44:139-266.
29. 29. Stephens RW, Pöllänen J, Tapiovaara H, Leung KC, Sim PS, Salonen EM, et al. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol 1989;108:1987-95.
30. 30. Liotta LA, Goldfarb RH, Brudage R, Siegal GP, Terranova V, Garbisa S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res 1981;41:4629-36.
31. 31. Werb Z, Mainardi CL, Vater CA, Harris-ED J. Endogenous activiation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med 1977;296:1017-23.
32. 32. DeClerck YA, Laug WE. Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression. Enzyme Protein 1996;49:72-84.
33. 33. Lyons RM, Keski-Oja J, Moses HL. Proteolytic activation of latent transforming growth factor-β from fibroblast-conditioned medium. J Cell Biol 1988; 106:1659-65.
34. 34. Ploug M, Rønne E, Behrendt N, Jensen AL, Blasi F, Danø K. Cellular Receptor for Urokinase Plasminogen Activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991;266:1926-33.
35. 35. Behrendt N, Ploug M, Patthy L, Houen G, Blasi F, Danø K. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem 1991;266:7842-7.
36. 36. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994;269:32380-8.
37. 37. Pöllänen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 1991;57:273-328.
38. 38. Miles LA, Plow EF. Ubiquitous sites for cellular regulation of fibrinolysis. Fibrinolysis 1988; 61-71.
39. 39. Ellis V, Scully MF, Kakkar VV. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 1989;264:2185-8.
40. 40. Myohanen HT, Stephens RW, Hedman K, Tapiovaara H, Rønne E, Høyer-Hansen G, et al. Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J Histochem Cytochem 1993;41:1291-1301.
41. 41. Andreasen PA, Kjøller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1-22.
42. 42. Lindahl TL, Sigurdardottir O, Wiman B. Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost 1989;62:748-51.
43. 43. Salonen EM, Vaheri A, Pöllänen J, Stephens R, Andreasen P, Mayer M, et al. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J Biol Chem 1989;264:6339-43.
44. 44. Cubellis MV, Wun TC, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 1990;9:1079-85.
45. 45. Nykjaer A, Conese M, Christensen EI, Olson D, Cremona O, Gliemann J, Blasi F. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J 1997;16:2610-20.
46. 46. Stephens RW, Tapiovaara H, Reisberg T, Bizik J, Vaheri A. Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells. Cell Regul 1991;2:1057-65.
47. 47. Deng G, Curriden SA, Wang SJ, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release. J Cell Biol 1996;134:1563-71.
48. 48. Alitalo K, Vaheri A. Pericellular matrix in malignant transformation. Adv Cancer Res 1982;37:111-58.
49. 49. Høyer-Hansen G, Rønne E, Solberg H, Behrendt N, Ploug M, Lund LR, et al. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 1992;267:18224-9.
50. 50. Solberg H, Rømer J, Brünner N, Holm A, Sidenius N, Danø K, Høyer-Hansen G. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int J Cancer 1994;58:877-81.
51. 51. Pedersen N, Schmitt M, Rønne E, Nicoletti MI, Høyer-Hansen G, Conese M, Giavazzi R, et al. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 1993;92:2160-7.
52. 52. Luther T, Magdolen V, Albrecht S, Kasper M, Riemer C, Kessler H, et al. Epitope-mapped monoclnal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am J Pathol 1997;150:1231-44.
53. 53. Rønne E, Høyer-Hansen G, Brünner N, Pedersen H, Rank F, Osborne CK, et al. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono-and poly-clonal antibodies. Breast Cancer Res Treat 1995; 199-207.
54. 54. Plesner T, Behrendt N, Ploug M. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells 1997;15:398-408.
55. 55. Wohn KD, Kanse SM, Deutsch V, Schmidt T, Eldor A, Preissner KT. The urokinase-receptor (CD87) is expressed in cells of the megakaryoblastic lineage. Thromb Haemost 1997;77:540-7.
56. 56. Rønne E, Pappot H, Grøndahl-Hansen J, Høyer-Hansen G, Plesner T, Hansen NE, Danø K. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Brit J Haematol 1995;89:576-81.
57. 57. Danø K, Behrendt N, Brünner N, Ellis V, Plough M, Pyke C. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibronolysis I994;8:189-213.
58. 58. Chavakis T, Kanse SM, Yutzy B, Lijnen HR, Preissner KT. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 1998; 91:2305-12.
59. 59. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. Proteolytic cleavage of the urokinase receptor subsitutes for the agonist-induced chemotactic effect. EMBO J 1996;15:1572-82.
60. 60. Høyer-Hansen G, Behrendt N, Ploug M, Danø K, Preissner KT. The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Letters 1997;420:79-85.
61. 61. Wilhelm O, Weidle U, Hohl S, Rettenberger P, Schmitt M, Graeff H. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett 1994;337:131-4.
62. 62. Luther T, Magdolen V, Albrecht S, Kasper M, Riemer C, Kessler H, et al. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am J Pathol 1997;150:1231-44.